STOK
NASDAQ
$27.68
Stoke Therapeutics Inc (STOK)
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops new antisense oligonucleotide (ASO) drugs to treat the underlying causes of serious genetic diseases in the United States. The company is headquartered in Bedford, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $45.82 (+65.53%)
Market Cap
$1.86B
FCF 5Y CAGR
+23.11%
Free Cash Flow Yield
-7.93%
Beta (5Y)
1.04
Price Chart
Valuation
Market Cap$1.86B
Forward P/E204.08
P/S58.07
P/B4.59
Profitability
Total Revenue (TTM)$32M
Gross Profit (TTM)$32M
EBITDA-$184M
Operating Margin-858%
EPS-$2.91
Financial Health
Free Cash Flow Yield-7.93%
Growth & Risk
EPS 5Y CAGR+11.95%
FCF 5Y CAGR+23.11%
Beta (5Y)1.04
Sharpe Ratio1.50